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Abstract
Background: Gliomas evade current therapies through primary and acquired resist-
ance and the effect of temozolomide is mainly restricted to methylguanin-O6-methyl-
transferase promoter (MGMT) promoter hypermethylated tumors. Further resistance 
markers are largely unknown and would help for better stratification.
Methods: Clinical data and methylation profiles from the NOA-08 (104, elderly 
glioblastoma) and the EORTC 26101 (297, glioblastoma) studies and 398 patients 
with glioblastoma from the Heidelberg Neuro-Oncology center have been analyzed 
focused on the predictive effect of DNA damage response (DDR) gene methylation. 
Candidate genes were validated in vitro.
Results: Twenty-eight glioblastoma 5'-cytosine-phosphat-guanine-3' (CpGs) from 
17 DDR genes negatively correlated with expression and were used together with 
telomerase reverse transcriptase (TERT) promoter mutations in further analysis. 
CpG methylation of DDR genes shows highest association with the mesenchymal 
(MES) and receptor tyrosine kinase (RTK) II glioblastoma subgroup. MES tumors 
have lower tumor purity compared to RTK I and II subgroup tumors. CpG hypo-
methylation of DDR genes TP73 and PRPF19 correlated with worse patient survival 
in particular in MGMT promoter unmethylated tumors. TERT promoter mutation is 
most frequent in RTK I and II subtypes and associated with worse survival. Primary 
glioma cells show methylation patterns that resemble RTK I and II glioblastoma and 
long term established glioma cell lines do not match with glioblastoma subtypes. 
Silencing of selected resistance genes PRPF19 and TERT increase sensitivity to te-
mozolomide in vitro.
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1 |  INTRODUCTION
Diffuse gliomas regularly evade current therapies and sev-
eral mechanisms behind resistance and sensitivity have not 
only recently been discovered with high-throughput efforts 
demonstrating the molecular faith of gliomas at recurrence,1 
but also novel targeted approaches proposing a novel radiation 
sensitivity biomarker.2 Classically, methylation of the methyl-
guanin-O6-methyltransferase promoter (MGMT) promoter is 
known to predict response to alkylating chemotherapy, with 
at best minimal responses for patients with an unmethylated 
MGMT promoter at diagnosis and progression.3,4 The NOA-08 
study demonstrated an impressive survival benefit in MGMT 
promoter methylated elderly patients with temozolomide treat-
ment compared to radiotherapy alone,5 but this may potentially 
be restricted to a specific molecular tissue context.6,7
Nevertheless, disease control for more than a few years 
is achieved in barely 15%-20% of younger glioblastoma pa-
tients with tumors with a hypermethylated MGMT promoter 
only. Therefore, further markers to better stratify patients for 
treatment response prediction and to decide for chemo- or ra-
diotherapy are of great interest. Recent approaches suggested 
that the DNA damage response (DDR) gene methylome could 
facilitate to predict resistance vs sensitivity to radio- and che-
motherapy in World Health Organization grade II, IDH mu-
tant gliomas.8 These markers have not been validated in an 
independent data set yet and an effect of differential DDR 
gene methylation in IDH wild-type glioblastomas dependent 
on the clinically relevant MGMT promoter methylation is 
unknown. Also, various inhibitors of DDR components are 
in preclinical and clinical development allowing to further 
exploit the concept of synthetic lethality.9,10
Recent studies suggested a benefit from a methylated 
MGMT promoter when receiving temozolomide chemother-
apy only in patients with tumors with additional promoter 
mutation of the DDR gene telomerase reverse transcriptase 
(TERT).11,12 We identified a subset of glioblastoma patients 
by methylation clustering, who benefitted most from temo-
zolomide treatment when the MGMT promoter is methylated. 
These patients showed enhanced TERT expression.6 In ad-
dition, TERT promoter mutation was found to be one of the 
earlier but not earliest events of gliomagenesis and leads to 
increased TERT expression rather than TERT methylation.13
Therefore, methylation of DDR genes and mutation status 
in particular for TERT may alter the sensitivity to standard 
radiochemotherapy treatment especially in tumors lacking 
MGMT promoter methylation. In these tumors prognostic 
factors are rarely known and would be important for patient 
stratification. We here explored the potential of DDR methyl-
ation as further prognostic markers. We based or hypothesis 
on 450 genes that have been identified as DDR genes14 and 
restricted the analysis to genes where methylation negatively 
impacted expression. Of the DDR genes, TERT is unique in 
the sense that TERT promoter mutations mainly influence 
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expression, and therefore, for TERT not methylation but the 
promoter mutations status was included. Based on these as-
sumptions, we aimed to identify prognostic markers of DDR 
genes in a combined analysis of three large well-documented 
glioblastoma cohorts from the NOA-087 and EORC 2610115 
studies as well as a patient cohort from our Heidelberg Neuro-
Oncology Center spanning a variety of conditions. Promising 
candidates are validated in vitro.
2 |  METHODS
2.1 | Patient cohorts
Two glioma studies and a well-documented cohort of patients 
treated in Heidelberg with study grade follow up that was 
used as an exploratory, hypothesis-generating data set were 
included in the present work. Altogether this study involves 
799 patients with diffuse IDH wild-type glioma. Regression 
analyses were performed either for each study separately or 
combined for all three studies together with correction for the 
confounding effect of the study, as indicated.
2.1.1 | NOA-08
The NOA-08 study compared radiotherapy (RT) with temozo-
lomide (TMZ) chemotherapy in elderly patients (age at diag-
nosis >65 years) with anaplastic astrocytoma or glioblastoma.5 
The original study population consisted of 373 patients. The 
investigated biomarker cohort consists of 104 patients (radio-
therapy group: 53, temozolomide group: 51).
2.1.2 | EORTC 26101
The EORTC 26101 study randomized patients with progres-
sive glioblastoma between bevacizumab (BEV) with lomustine 
(CCNU) and CCNU alone.15 The original study cohort con-
sisted of 596 patients. The investigated biomarker cohort where 
methylation array data and paraffin tissue for evaluating TERT 
mutations status was available consisted of 297 patients.
2.1.3 | Heidelberg cohort
About 398 patients from the Heidelberg Neuro-Oncology 
center diagnosed with IDH wild-type glioblastoma between 
07/2014 and 01/2018 based on histopathological and molecu-
lar characteristics. This cohort includes 43 patients from the 
NCT Neuro Master Match (N2M2) pilot study extensively 
characterized with whole-genome sequencing, whole-exome 
sequencing (WES), RNAseq, and methylation analysis.16
Inclusion of patients into this analysis is covered by a 
local Heidelberg ethics vote (no. S307/2019).
Patients of the two clinical study biomarker cohorts (NOA-
08 and EORTC-26101) are comparable to the original study 
population regarding survival times and treatment (Table 1).
Biomarker cohort Full study cohort
NOA-08
Patient number [n (%)] 104 (28%) 373 (100%)
Overall survival [median (95% CI)]a 11.2 (9.6-13.8) 8.7 (8.0-9.8)
Event-free survival [median (95% CI)]a 4.1 (3.7-4.5) 4.4 (3.6-5.5)
TMZ group [n (%)] 51 (49%) 195 (52%)
RT group [n (%)] 53 (51%) 178 (48%)
EORTC-26101
Patient number [n (%)] 297 (50%) 596 (100%)
Lomustine first group [n (%)] 117 (39%) 231 (39%)
BEV ± Lomustine first group [n (%)] 180 (61%) 365 (61%)
Overall survival [median (95% CI)]a 8.6 (7.9-9.9) 8.9 (8.2-9.6)
Progression-free survival [median (95% CI)]a 3.0 (2.8-3.7) 2.9 (2.8-3.0)
Heidelberg cohort
Patient number [n] 398 NA
Overall survival [median (95% CI)]a 24.9 (19.2-31.0) NA
Progression-free survival [median (95% CI)]a 8.2 (7.2-9.2) NA
Patients with RT + TMZ [n (%)] 252 (63%) NA
Abbreviations: BEV, bevacizumab; RT, radiotherapy; TMZ, temozolomide.
aSurvival times are given in months. 
T A B L E  1  Comparison of Biomarker 
cohorts in the present analysis with the 
original study cohorts.
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2.2 | Illumina HumanMethylation450 and 
HumanMethylationEPIC arrays
The Illumina Infinium HumanMethylation450 (450k) 
bead chip and MethylationEPIC kits were used to obtain 
the DNA methylation status at >450  000 and >850  000 
5'-cytosine-phosphat-guanine-3' (CpG) sites, respectively 
(Illumina), according to the manufacturer's instructions at 
the Genomics and Proteomics Core Facility of the German 
Cancer Research Center (DKFZ) in Heidelberg, Germany 
from fresh frozen and paraffin embedded tissue of study 
cohorts as well as selected primary patient-derived cul-
tures. Samples were analyzed using the R (www.r-proje 
ct.org) based methylation pipeline “ChAMP” 2.10.1.17 In 
brief, filtering was done for multihit sites, SNPs, and XY 
chromosome-related CpGs, then, data were normalized 
with a BMIQ based method and analyzed for batch effects 
with a singular value decomposition algorithm. Batch ef-
fects related to the tissue used (paraffin embedded [FFPE] 
vs fresh frozen [KRYO]) were corrected using ComBat. 
MGMT promoter methylation status was determined by the 
algorithm of Bady et al.18 The classifier score and associa-
tion with specific classifier types (RTK I, II, and MES) was 
performed using the Neuropathology 2.0 tool described in 
Capper el al.19 Custom scripts based on the R packages 
“minfi” (version 1.26.2) and “conumee” (version 1.14.0) 
were implemented for copy-number variation profiling and 
visualization.
2.3 | Tumor purity estimation
Tumor purity estimation was performed on normalized beta 
values of methylation data with the R package InfiniumPurity 
version 1.3.1.20
2.4 | Selection of functional DDR gene 
methylation CpGs
Potential DDR genes were obtained from a 450 putative gene 
list that was published previously.14 CpGs present in the 450k 
methylation array in the promoter region were tested for 
negative association with expression in The Cancer Genome 
Atlas (TCGA, RRID:SCR_003193) data set obtained from 
the National Cancer Institute Genomic Commons Data Portal 
(GDC Portal, portal.gdc.cancer.gov). CpGs with a correlation 
r < −.3 and a Benjamini-Hochberg adjusted P < .05 were re-
garded as “functional” in a sense that high methylation cor-
relates with low RNA expression. About 28 CpGs from 17 
genes met this criterion and were used for further analysis. The 
thereafter used term “functional DDR CpGs” refers to these 
28 CpGs.
2.5 | Cell culture and in vitro assays
A detailed description of in vitro assays is given in the 
Methods S1. Generation and maintenance of established 
glioma cell lines and primary glioma cell cultures was per-
formed using standard methods as described previously.21,22
2.6 | Data analysis
Statistical analyses were carried out with R 3.5.1 (www.r-
proje ct.org, RRID:SCR_001905) and Microsoft Excel 2016 
(Microsoft Corporation; RRID:SCR_016137). If not oth-
erwise stated, a P <  .05 was considered as significant and 
marked with a “*.” No outliers have been excluded. Correction 
for testing of multiple CpGs or genes was performed using 
the Benjamini-Hochberg procedure. The performances of 
the multivariate proportional hazards models were calculated 
using a c-index concordance statistic in R. If not otherwise 
indicated bar charts show mean values and standard devia-
tion of at least three independent experiments. For survival 
analysis, we used custom adaptations of the R packages “sur-
vival” (version 2.42-6) and “survminer” (version 0.4.3). A 
Cox proportional hazards model for univariate and multivari-
ate analysis was used to assess the correlation between CpG 
methylation and survival as implemented in the “coxph” 
function. Clustering of methylation array samples was done 
as described before6 using the ConsensusClusterPlus pack-
age in R. Dimensionality reduction and network analysis 
were also performed with R and are described in the Methods 
S1. All figures were produced using R-based packages.
2.7 | Data availability
Methylation raw and processed data are made accessible 
via the Gene Expression Omnibus (GEO) database (https://
www.ncbi.nlm.nih.gov/geo/; RRID:SCR_005012) under the 
GEO accession numbers GSE12 2920 (NOA-08 biomarker 
cohort), GSE14 3755 (EORTC 26101 biomarker cohort), 
GSE12 2994 and GSE143842 (both Heidelberg cohort). 
TCGA data from glioblastoma patients can be accessed via 
CDC portal (portal.gdc.cancer.gov).
3 |  RESULTS
3.1 | The functional DDR methylome of IDH 
wild-type glioblastoma
Figure S1 shows the workflow of the project and study co-
horts used. DDR CpGs were derived from a list of 450 previ-
ously published expert-curated human DDR genes.14 We then 
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correlated RNA expression of these genes with CpG meth-
ylation in the TCGA glioblastoma data set and negatively 
correlated CpGs (r < −.3, P.adj < .05, see Section 2) were re-
garded as functional and used for further analysis. In total, 28 
CpGs from 17 genes were identified (Table S1). Additionally, 
TERT expression correlates with TERT promoter mutations 
in samples from Heidelberg, for which expression and muta-
tion data were available (Figure S2). Mutation frequencies of 
DDR genes excluding TERT were rather low in the TCGA 
glioblastoma data set with only three genes exceeding a pre-
defined 3% mutation frequency in the TCGA glioblastoma 
data set (STAG [5%], TP53 [53%], ATRX [9%]) all without 
harboring functional CpGs in their promoter. Similar results 
were obtained in the WES Heidelberg glioblastoma IDH 
wild-type cohort (n = 43). Figure 1A,B show a heatmap with 
methylation values of functional DDR CpGs together with 
methylation classifier assignments of all 799 IDH wild-type 
tumors from the EORTC26101, NOA-08, and Heidelberg 
cohorts. Hierarchical clustering divides the CpGs into four 
different groups, those with generally low methylation, high 
methylation, and two groups with a broad range of methyla-
tion values (Figure S3).
Principle component analysis of DDR methylation re-
veals two main directions. Dimension 1 (24.3% variance) is 
dominated by XRCC3, CUL4A, and CSK1E and dimension 2 
(11.1% variance) by POLE4 and TP73 (Figure 2A). Tumor 
purity was estimated from methylation data and is strongly 
associated with dimension 1, highlighting the importance of 
tumor purity on methylation profiles (Figure  2B). Tumors 
with mesenchymal (MES) classifier assignment differed 
F I G U R E  1  Functional DNA damage response 5'-cytosine-phosphat-guanine-3' (CpG) methylation in clinical study cohorts. Heatmaps 
of functional CpGs of all three studies (NOA-08, n = 104, EORTC 26101 , n = 297 and Heidelberg, n = 398) combined showing normalized 
methylation beta values (A) and row scaled values (B). 5ʹ-UTR, 5ʹ untranslated region; chr, chromosome; TSS200, 0-200 base pairs upstream of 
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from the RTK I and RTK II tumors (Figure 2C,D). We an-
alyzed the association of the methylation of single DDR 
CpGs with classifier assignments in the study cohorts, with 
a cutoff P < .001 (Figure 2E). Distribution of gene methyl-
ation was similar in all three investigated glioblastoma co-
horts. Methylation of POLE4 and MVP was highest in RKT 
II tumors, whereas most other genes including XRCC3 and 
CSNK1E were hypermethylated in mesenchymal classified 
tumors. Mean MGMT methylation was lowest in mesenchy-
mal tumors; however, highest percentage of MGMT unmeth-
ylated tumors was found in the RTK I subgroup. Comparison 
between average DDR methylation and global methylation 
revealed similar patterns with RTK I tumors having lowest 
methylation levels (P < 2.2 × 10−16 for both MES and RTK 
II against RTK I, Figure S4A,B).
Tumor purity might influence the prognostic effect of 
CpG methylation. Mesenchymal tumors had an average lower 
tumor purity compared to RTK I or RTK II tumors (median: 
0.57 vs 0.79 and 0.75, P < 1 × 10−57 for both comparisons, 
Figure  2F). This may additionally explain the on average 
lower MGMT promoter methylation level. Conclusively, 
XRCC3, CUL4A, and CSK1E methylation highly correlated 
with tumor purity (Figure 2G; Figure 4SC-F).
3.2 | DDR methylome and interaction 
with therapy outcome in glioblastoma
A univariate cox proportional hazard model was applied to 
identify survival associated functional CpGs. There were 
five genes identified in the exploratory Heidelberg cohort, 
which were associated with overall survival (OS). Of these, 
only MGMT promoter methylation was correlated with better 
prognosis consistently in all three studies (Data S1).
In a pooled multivariate cox analysis of all three stud-
ies seven genes prove to be independent markers in both 
OS and progression-free survival (PFS) after correcting for 
MGMT promoter methylation status and multiple testing 
(Data S1). Beforehand analysis revealed that the criterion 
of proportionality was not violated. Further analysis sep-
arated by MGMT promoter methylation revealed that four 
of the DDR genes (TP73, CSNK1E, EXO1, and PRPF19) 
showed significant association with OS and PFS only in 
MGMT unmethylated tumors (Data S2). Moreover, after 
addition of tumor purity into the multivariate model, only 
PRPF19 (P  =  .005-.04, c-index  =  0.71-0.73) and TP73 
(P =  .02-.04, c-index = 0.71-0.72) methylation were sig-
nificantly associated with better OS and PFS (Data S2). 
C-indices for multivariate analyses ranged for significant 
CpGs between 0.66 ± 0.02 and 0.73 ± 0.02 confirming on 
average good performance of the models (see respective 
Supporting Information Data).
The recent NOA-08 long term study analysis showed 
worse outcome of patients in the RTK I subgroup in our 
Heidelberg and the NOA-08 biomarker cohort7 as well as 
the best prognosis for patients with MGMT promoter meth-
ylated tumors with a RTK II classifier assignment. Though 
with a global P-value of .058 not significant, there was a 
trend also in the EORTC 26101 recurrent glioblastoma study 
toward worse survival of patients with the low methylated 
RTK I tumors (Figure 5A). Furthermore, recent preliminary 
data link EGFRvIII to a better prognosis in MGMT meth-
ylated tumors.23 In concordance, we found EGFRvIII and 
EGFR amplification both highest in the RTK II subgroup 
(Figure 5C,D) as one potential factor driving chemotherapy 
sensitivity in RTK II tumors.
Focusing on subtype-specific CpG markers, we identified 
only MGMT promoter methylation specifically correlating 
with improved survival in RTK II tumors, MVP was prog-
nostic in RTK I tumors and no CpG was prognostic in MES 
subgroup tumors (Data S3).
The NOA-08 study with the chemotherapy vs radiother-
apy regimen additionally offers the chance of finding CpGs 
that are specifically associated with benefit from either treat-
ment. MGMT, GEN1, PARP4, and CSNK1E were found to be 
associated with better survival in the chemotherapy group, 
whereas TP73 and CCND3 methylation were linked to ra-
diotherapy sensitivity in the OS analysis, however, none of 
these reached significance after correction for multiple test-
ing (Data S4). For PFS, only MGMT was prognostic in the 
chemotherapy group.
3.3 | The association of TERT 
promoter mutation with methylation 
profiles and survival
In the two cohorts with available TERT status, TERT pro-
moter mutation was found in 377 of 455 (83%) patients. 
Differences were noted between both cohorts (EORTC 26101 
F I G U R E  2  DNA damage response (DDR) methylation profiles. A, Principle component analysis (PCA) showing 5'-cytosine-phosphat-
guanine-3' (CpG) direction. B, PCA with samples colored by Classifier assignment with the 25 DDR CpGs (C) and the 5000 most variable CpGs 
(D). E, Methylation of DDR CpGs according to the three most abundant glioblastoma subgroups (MES, RTK I, and RTK II). F, Tumor purity 
according to tumor subtype. G, Example of correlation between tumor purity and XRCC3 methylation. 5ʹ-UTR, 5ʹ untranslated region; av., average; 
cont., contribution to a principle component; meth., methylation; TSS200, 0-200 base pairs upstream of transcription start site, TSS1500: 200-1500 
base pairs upstream of transcription start site; PCA1, principle component 1; PCA2, principle component 2; a full list of classifier abbreviations can 
be found in the Supporting Information
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88%, Heidelberg cohort 72%). TERT promoter mutation was 
predominantly found in the three main glioblastoma groups 
(MES, RTK I, and RTK II). For TERT wild-type tumors 21% 
belong to these groups, as well as 14% of the TERT mutated 
do (Figure 3A). TERT wild-type status was associated with 
better PFS in the Heidelberg cohort, but not in the recurrent 
EORTC 26101 cohort (Figure 3B,C). We restricted the anal-
ysis to RTK I, RTK II, MES, Midline, and MYCN18 tumors 
and found 500 differentially methylated CpGs compared to 
>10  000 differential CpGs in the unrestricted analysis un-
derling the effect of the glioma classification over TERT 
mutation. Differentially methylated regions showed high 
overlap between C228T and C250T tumors (Figure 3D). On 
chromosome 2, a cluster of DMRs in the promoter regions of 
HOXD genes was identified (Figure 3E). A weighted-gene 
correlation network analysis (WGCNA) identified 30 mod-
ules of CpGs within the EORTC 26101 data set (Figure 3F). 
Most modules correlated strongly with tumor purity and dif-
ferentiated between the RTK I, RTK II, and MES subtypes. 
Highest correlation to TERT promoter mutation status was 
conclusively found in a module specific for the RTK I pheno-
type with CpGs restricted to chromosome 2 in the HOXD12, 
HOXD4, HOXD3, and MIR10B promoters. However, no spe-
cific survival associated module was correlated with TERT 
promoter mutation. Copy-number analysis revealed associa-
tion of TERT mutation with amplification of chromosome 7 
and loss of chromosome 10, for example, with a typical glio-
blastoma phenotype in differential and WGCNA analysis.
3.4 | DDR genes and therapy response in 
glioblastoma cell lines and primary glioma 
cell cultures
TERT status, DDR methylome, MGMT promoter meth-
ylation and methylation patterns in primary glioblastoma 
cell cultures and cell lines are depicted in Figure  4A. 
Hierarchical clustering separated adherently growing 
cell lines from primary cells based on DDR methyla-
tion. All samples harbor either TERT promoter mutation 
C228T or C250T, all but one (9/10) are MGMT methylated 
(Table  S2). Methylation is retained in cell culture as all 
but one (5/6) primary cell lines show a matching profile 
with one of the main glioblastoma methylation subgroups. 
Of note, adherent cell lines grown in serum change their 
methylation profile in cell culture being most conclusive 
with a pediatric plexus tumor while copy number variation 
(CNV) profiles still allow identification as derived from 
glioblastoma (Table  S2; Figure S6). T-SNE analysis of 
methylation patterns shows clear separation between cell 
lines and primary cultures as well as IDH wild-type glioma 
samples (Figure 4B).
PRFP19 methylation was associated with survival in 
the combined analysis and in particular in MGMT promoter 
unmethylated, therefore, mainly temozolomide resistant, tu-
mors and retained significance after controlling for tumor 
purity. Therefore, besides TERT promoter mutation, PRPF19 
methylation might be an interesting prognostic marker. We 
independently confirmed a negative correlation between 
PRPF19 methylation and expression (Figure 4C; r = −.39) 
and positive correlation of TERT mutation and TERT expres-
sion in the subset of the Heidelberg cohort with available ex-
pression data (Figure S2). Low methylation/high expression 
primary glioma cultures were picked for lentiviral gene ex-
pression modulation of PRPF19 and TERT. Knockdown of 
PRPF19 and TERT was validated via quantitative real-time 
PCR (Figure S7) and resulted in an enhanced response to te-
mozolomide treatment. Cell cycle analysis revealed a higher 
proportion of G2 arrested cells after temozolomide treatment 
in tumor cells deficient of PRFP19 and TERT compared to 
equally treated tumor cells transfected with respective control 
vector (Figure  4D,E,H). Similarly, clonogenicity of tumor 
cells treated with temozolomide was reduced particularly in 
PRPF19 and TERT knockdown cells (Figure 4F,G,I). These 
effects were not observed for irradiation with both knock-
downs (Figure  S8). A summary with relevant findings is 
given in Figure 5A,B.
4 |  DISCUSSION
With this cross-study analysis based on large recent cohorts 
of glioblastoma patients, we provide evidence for a prognos-
tic role of DDR genes including DDR methylome and TERT 
promoter mutation status. In our view, this holds several im-
portant implications:
Besides the well described DDR gene MGMT, we identi-
fied DDR genes for which methylation is linked to survival, 
in particular in patients with MGMT promoter unmethylated 
tumors. This is of particular interest as these tumors at best 
F I G U R E  3  Correlation of telomerase reverse transcriptase (TERT) status with glioblastoma subgroups. A, TERT promoter mutation status and 
tumor classifier subgroup. Survival analysis of patients with primary glioblastoma (B) Heidelberg cohort and recurrent glioblastoma (C) EORTC 
26101 cohort. D, Visualization of genome distribution of differential methylated regions between TERT promoter mutated and wild-type tumors. 
E, Differential methylated regions on chromosome 2 in C225T (upper row) and C250T (lower row) tumors. F, Heatmap of different 5'-cytosine-
phosphat-guanine-3' modules as the result of the WGCNA analysis and relationship to several tumor-specific markers. C225T, C250T, mutation 
location upstream of the TERT transcription start site; chr2, chromosome 2; PFS, progression-free survival; Mb, megabase; OS, overall survival, a 
full list of classifier abbreviations can be found in the Supporting Information
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have very limited response to standard chemotherapy with 
temozolomide and since further prognostic molecular factors 
have remained elusive. In our analysis, we identified methyl-
ation of the two DDR genes PRPF19 and TP73 significantly 
associated with better OS and PFS in particular in patients 
with MGMT promoter unmethylated tumors in our multivar-
iate analysis. PRPF19 was previously reported to be involved 
in DDR24 and has a potential role in oncogenesis,25 but lit-
tle is known about its function in glioblastoma. TP73 is a 
member of the TP53 gene family and overexpressed in a vari-
ety of cancers.26,27 Its regulation is complex and not fully un-
derstood, especially the association between methylation and 
gene expression is a controversy in different cancers,26,28 but 
a regulatory role in chemotherapy response and probably sen-
sitivity through DNA methylation has been described.29 We 
here describe a negative association between methylation and 
expression for the prognosis relevant CpG cg13943358 and 
cg2316013 in glioblastoma. The association in chemotherapy 
response makes both genes very plausible markers for glioma 
prognosis in the absence of MGMT methylation as a sensitiv-
ity factor against chemotherapy, however, formal testing for 
a predictive effect of the methylation levels of both genes on 
chemotherapy response was not in the intention of the study 
and the analysis comparing different treatment methods in 
the NOA-08 cohort lacks sufficient sample size for difference 
detection, and therefore, regarded as exploratory.
Functional evidence for chemosensitivity, however, 
was validated for PRPF19 by gene silencing in glioblas-
toma cells. Depletion of PRPF19 expression resulted in the 
anticipated sensitization to temozolomide in glioblastoma 
cell lines and primary cell cultures, and may therefore, 
be investigated further as a predictive marker in MGMT 
promoter unmethylated glioblastoma. A limitation to use 
PRPF19 methylation as prognostic marker is its overall rel-
atively low methylation, but combination with expression 
may improve prognostic relevance. The TP73 gene was not 
functionally analyzed in this study, but represents an at-
tractive area for further research. The effect of upfront al-
kylating agents vs targeted treatments in MGMT promoter 
unmethylated glioblastoma on its prognostic impact could 
be answered by subgroup analysis of our currently recruit-
ing N2M2 clinical study.30
RTK I glioblastomas remain a less understood, poorly 
performing group that have lower DDR and overall meth-
ylation levels. Only MVP methylation was prognostic in 
this group, however, overall promoter methylation of this 
F I G U R E  4  DNA damage response (DDR) genes and therapy response in glioblastoma cells. A, DDR methylome, telomerase reverse 
transcriptase (TERT) status, MGMT promoter methylation and methylation patterns in primary glioblastoma cell cultures and cell lines. B, T-SNE 
analysis of cell lines, primary cell cultures and IDH wild-type samples. C, Correlation between PRPF19 methylation and expression. D, Cell cycle 
analysis in LN308 cells, silenced for PRPF19 or transfected with respective control vector, after treatment with 5 µmol/L of temozolomide or 
dimethyl sulfoxide (DMSO) as control. Two different knockdown constructs were used for analysis. E, Cell cycle analysis in S24 cells, silenced 
for PRPF19 or transfected with respective control vector, after treatment with 100 µmol/L of temozolomide or DMSO as control. Two different 
knockdown constructs were used for analysis. F, Clonogenicity of LN-308 cells, silenced for PRPF19 or transfected with respective control vector, 
after treatment with 5 µmol/L of temozolomide or DMSO as control. Two different knockdown constructs were used for analysis. G, Clonogenicity 
of S24 cells, silenced for PRPF19 or transfected with respective control vector, after treatment with 100 µmol/L of temozolomide or DMSO as 
control. Two different knockdown constructs were used for analysis. H, Cell cycle analysis in LN308 cells silenced for TERT or transfected 
with respective control vector, after treatment with 5 µmol/L of temozolomide or DMSO as control. Two different knockdown constructs were 
used for analysis. I, Clonogenicity in LN-308 silenced for TERT or transfected with respective control vector, after treatment with 5 µmol/L of 
temozolomide or DMSO as control. Two different knockdown constructs were used for analysis. For panels D-I the mean value and SD of three 
independent experiments is shown. *P < .05. 5ʹ-UTR: 5ʹ untranslated region; chr, chromosome; TSS200, 0-200 base pairs upstream of transcription 
start site; TSS1500, 200-1500 base pairs upstream of transcription start site
F I G U R E  5  Summary of relevant findings. A, Methylation 
analysis of 450 DNA damage response (DDR) genes revealed 17 
functional DDR genes of which in seven genes hypomethylation 
showed association with reduced survival. Hypomethylation of 
PRPF19 and TP73 was associated with worse survival in patients 
with MGMT promoter unmethylated tumors with adjustment for 
tumor purity. TERT promoter mutations were correlated with 
methylation groups and survival times. B, PRPF19 and TERT k/d-
induced sensitivity in glioblastoma cells toward temozolomide but 
not radiotherapy. k/d, knock down; MGMT, unmethylated MGMT 
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gene was low challenging its suitability as a robust marker. 
Further studies might dive deeper into the differences es-
pecially between RTK I and II tumors and their differential 
methylation profiles.
Further limitations of this methylation analysis approach 
include the heterogeneity of the three well-documented patient 
cohorts used that might reduce sensitivity for markers poten-
tially present only in certain subgroups, but enables to cover a 
variety of conditions for detection of strong universal markers. 
Even the NOA-08 study compared radiotherapy vs chemother-
apy the methylation analysis was not powered nor intended to 
detect chemosensitivity of certain CpGs. Furthermore, the co-
horts based on the two large studies EORTC 26101 and NOA-
08 were subsets of the original study population based on the 
availability of tissue for methylation array analysis. Therefore 
a sampling bias that often tends toward a better prognosis in 
the biomarker cohorts cannot be fully excluded. The approach 
to include only CpGs with negative correlation of methylation 
with expression in glioblastoma ensures a higher chance of 
finding functionally relevant genes from a small defined set, 
but may not be exhaustive as also a subset of CpGs with pos-
itive correlations of methylation and expression or CpGs not 
captured by the stringent threshold could be robust prognostic 
factors though complex regulations.
TERT promotor mutation is the main factor facilitating 
TERT expression and several studies reported differential out-
comes based on TERT mutation and MGMT promoter methyla-
tion,6,11,12 this should be taken with caution as these might have 
included patients with nonglioblastoma methylation groups as 
a potential confounder. Here, we demonstrated that TERT mu-
tation is associated with worse survival in well characterized 
cohorts and silencing of TERT expression in glioma tumor cells 
was associated with an enhanced response to temozolomide 
treatment.
This study furthermore holds implications for preclinical 
models. Primary glioma cultures nicely retain the glioblasto-
ma-like methylation state, whereas cell lines change to a meth-
ylation profile most consistent with a pediatric plexus tumor. 
Although we have observed similar results for our functional 
studies between primary glioma cells and adherent cell lines 
and both models cluster outside the patient tumor samples, 
the methylation profiling strongly encourages the use of pri-
mary cell lines as an appropriate model glioma for glioma 
biology as they retain a well-preserved glioma methylation 
phenotype. Of note, we have not observed a glioblastoma 
MES primary cell line in our sample. This might be because 
of the relatively low number of primary cell lines (n = 9), but 
the lower tumor purity in MES glioblastomas might prevent 
detection of this phenotype in cell culture.
In summary, low methylation of DDR genes and TERT 
promoter mutation are associated with worse prognosis in 
glioblastoma patients and current studies on DDR inhibitors 
with and without other cytotoxic or immunological therapies 
may finally yield benefit especially for the heavily under-
served patient population with tumors having an unmethyl-
ated MGMT promoter.
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